AstraZeneca (AZN) Says IMFINZI Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable NSCLC
Tweet Send to a Friend
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
